Effect of parecoxib on postoperative anxiety and cognitive function after pancreaticoduodenectomy: A clinical trial

Clinical Snapshot

Key Findings

• P Value: P < 0.05 for anxiety scores; P > 0.05 for PND incidence

• Effect Size: PND incidence reduced from 12.5% (control) to 5% (parecoxib group)

• Primary Outcome: Lower State Anxiety Inventory scores at 24 hours postoperatively in parecoxib group (P < 0.05)

• Nnt Or Sensitivity: Number needed to treat approximately 13 patients to prevent one case of PND (based on 7.5% absolute risk reduction)

• Confidence Interval: Not reported

Clinical Application

Parecoxib readily available and easy to administer perioperatively. Low-risk intervention with established safety profile Parecoxib listed on PBS for postoperative pain management. TGA-approved COX-2 inhibitor. Consistent with ANZCA perioperative medicine guidelines for multimodal analgesia Adult patients undergoing major pancreatic surgery, particularly laparoscopic pancreaticoduodenectomy

Abstract

BACKGROUND: After pancreaticoduodenectomy, perioperative neurocognitive disorders (PND) are a common complication. Parecoxib, a selective cyclooxygenase-2 inhibitor, is used for its analgesic and antiinflammatory effects, but its impact on postoperative anxiety and cognitive function is not clear. METHODS: The patients undergoing laparoscopic pancreaticoduodenectomy at the Second Hospital of Hebei Medical University were enrolled in the study from November 1, 2020 to September 30, 2022 in this randomized controlled trial. Patients were randomly divided into Group P who received 20 mg of parecoxib intravenously 10 minutes before anesthesia and at the end of surgery and Group C who received an equal volume of normal saline at the same times. Primary outcomes included the effect of parecoxib on anxiety, cognitive impairment, and postoperative intestinal function recovery, with the incidence of PND calculated using the Z-value method. Secondary outcomes included pain control, length of hospital stay, postoperative recovery, complication rates, and analgesic use. RESULTS: 80 patients were enrolled and randomly divided into 2 groups of 40 equally: there were no significant differences in postoperative flatus passage, defecation time, hospital stay, or complication rates (P > .05). In terms of postoperative anxiety, the experimental group had significantly lower State Anxiety Inventory scores at 24 hours postoperatively (T2) (P < .05). Cognitive function, measured by Montreal Cognitive Assessment scores, did not show significant differences; however, cognitive decline was less pronounced in the experimental group. PND rates were 5% (2/40) in the experimental group versus 12.5% (5/40) in the control group, suggesting a possible clinical tendency toward reduced incidence, although the difference did not reach statistical significance. The rates of PND at 24 hours (T2) and 7 days (T3) postoperatively were 10% (4/40) and 5% (2/40) for the experimental group, compared to 15% (6/40) and 12.5% (5/40) for the control group using the Z-value method, Although the between-group differences did not reach statistical significance, a lower incidence was observed in the parecoxib group, suggesting a possible clinical tendency. CONCLUSION: Parecoxib, when used with pancreaticoduodenectomy, alleviates postoperative anxiety and neurocognitive disorders without affecting postoperative intestinal function recovery or increasing the incidence of postoperative complications.

References

1. 1.Zhang, F., Ma, L., Li, X., Wang, S., & Di, L. (2026). Effect of parecoxib on postoperative anxiety and cognitive function after pancreaticoduodenectomy: A clinical trial. Medicine, 105(16), e48330. https://doi.org/10.1097/MD.0000000000048330